<DOC>
	<DOCNO>NCT01885117</DOCNO>
	<brief_summary>The present study design confirm safety immunogenicity trivalent , surface antigen , inactivate influenza vaccine 2 age cohort : 18 ≤60 year ≥61 year antibody response influenza vaccine antigen , measure Single Radial Hemolysis ( SRH ) Hemagglutination Inhibition ( HI ) approximately 21 day post immunization . The vaccine composition base World Health Organization ( WHO ) recommend influenza strain 2013/2014 Northern Hemisphere vaccine . The result study intend support use vaccine future influenza season recommend vaccine composition remain , compliance requirement current European Union ( EU ) recommendation clinical trial relate yearly license influenza vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity One Dose Seasonal Trivalent Influenza Virus Vaccine ( TIVf , Purified Surface Antigen , Inactivated , Egg Derived ) Adults , Aged 18 Years Above</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female volunteer age 18 year old , mentally competent , give write informed consent prior study entry ; Able comply study requirement ; In good health determine outcome medical history , physical examination , clinical judgment investigator Any behavioral cognitive impairment psychiatric disease , opinion investigator , may interfere subject 's ability participate study ; serious chronic acute disease ( judgment investigator ) include , limited medically significant cancer ( except benign localize skin cancer , cancer remission ≥10 year , localized prostate cancer clinically stable &gt; 2 year without treatment ) medically significant advanced congestive heart failure ( ie , New York Heart Association ( NYHA ) class III IV ) chronic obstructive pulmonary disease ( ie , Global initiative chronic Obstructive Lung Disease ( GOLD ) stage III IV ) autoimmune disease ( include rheumatoid arthritis except Hashimoto 's thyroiditis clinically stable ≥5 year ) diabetes mellitus type I poorly control diabetes mellitus type II advance arteriosclerotic disease history underlie medical condition major congenital abnormality require surgery , chronic treatment , associate developmental delay ( Down 's syndrome ) , acute progressive hepatic disease acute progressive renal disease severe neurological ( especially GuillainBarré syndrome ) psychiatric disorder severe asthma history anaphylactic reaction and/or serious allergic reaction component study vaccine ; know suspect ( high risk develop ) impairment/alteration immune function ( exclude normally associate advanced age ) resulting , example , : receipt immunosuppressive therapy ( parenteral oral corticosteroid cancer chemotherapy/radiotherapy ) within past 60 day full length study , receipt immunostimulants within past 6 month , receipt parenteral immunoglobulin preparation , blood product , and/or plasma derivates within past 3 month full length study , suspect know human immunodeficiency virus ( HIV ) infection HIVrelated disease Had know suspect drug alcohol abuse within past 2 year ; Had bleed diathesis condition associate prolonged bleeding time , investigator 's opinion , would interfere safety subject ; able comprehend follow require study procedure whole period study ; Had history illness , opinion investigator , would pose additional risk subject participation study ; Had follow within past 6 month : laboratoryconfirmed seasonal pandemic influenza disease receive seasonal pandemic influenza vaccine Had receive vaccine within 4 week prior enrollment study planning receive vaccine study ; Had acute chronic infection require antiviral therapy within last 7 day ; Had experience fever ( ie , body temperature [ preferably oral ] ≥38.0°C ) within last 3 day intend study vaccination ; Had participate clinical trial another investigational product 4 week prior first study visit intend participate another clinical study time conduct study ; part study personnel close family member conduct study ; Had body mass index ( BMI ) &gt; 35 kg/m2 ( BMI calculate divide subject 's weight kilogram subject 's height meter multiply subject 's height meter ) ; pregnant ( confirm positive urine pregnancy test ) nursing ( breast feeding ) female childbearing potential refuse use acceptable method birth control whole duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Influenza ,</keyword>
	<keyword>Adults ,</keyword>
	<keyword>Elderly ,</keyword>
	<keyword>Immunology ,</keyword>
	<keyword>Safety</keyword>
</DOC>